COLORADO SPRINGS, Colo.,
Oct. 25, 2013 /PRNewswire/ -- Endocan
Corporation (NASDAQ OTC: XCHC), a U.S. Company specializing in
cannabis and cannabinoid formulation-based health and wellness
solutions worldwide, is pleased to make public the Company's
on-going negotiations with third parties in Colorado to initiate cooperative and joint
venture arrangements for production, testing, and distribution of
products under the Endocan™ brand name. This includes the
long awaited Endocan product line expected for release in early
2014, with Colorado as an early
target market in the United States
for testing in several critical ailment categories (see more at
http://www.endocan.com/products/critical-ailments).
Endocan Corporation's presence in Colorado stems not only from the legal medical
cannabis regulatory environment but also from the general openness
with which Colorado has embraced
cannabis, including the extension of legalization to recreational
cannabis use for individuals over the age of 21, with a forward
looking regulatory and taxation policy. This environment
speaks highly of the future of Endocan Corporation's development
opportunities in the state, which has an estimated $200 million medical cannabis market at this
early stage.
Robert Kane, CFO & Senior
Vice President of Business Development of Endocan Corporation,
stated, "Colorado has now been my
home for 3 years, my family having relocated to Colorado
Springs. We have found Colorado to be a progressive, open-minded
state with a compassionate position on improving the quality of
life of its citizens. The backdrop to Colorado's first-in-nation approach to a
sensible treatment of cannabis and hemp is the ability in the state
for Endocan Corporation to innovate in its mission to deliver
top-quality cannabis and cannabinoid based patient care.
Other jurisdictions will inevitably follow Colorado's lead in the U.S., and we want to be
at the forefront of each of these burgeoning markets with
Colorado as a model."
About Endocan Corporation
The brand name Endocan™ was chosen by the Board as a direct
reference to the endocannabinoid system of the human body. The
endocannabinoid system is a group of neuromodulatory compounds and
their receptors that are involved in a variety of fundamental
physiological processes including pain-sensation, immune function,
stress, sleep, mood, appetite, and memory. Cannabinoids from
plants, including those found in the Cannabis genus, as well as
those autonomously produced within living biological systems, work
together in the operation of the endocannabinoid system. The
modulation of this system is the basis for cannabinoid-based
medical treatments to assist patients to improve their health and
well-being.
Endocan Corporation, (FKA The X-Change Corporation), is
currently developing new natural cannabinoid containing products
based on innovative formulations to utilize the unique and potent
benefits of the cannabis and hemp plants. Medicinal properties of
cannabis and hemp have been known and applied for thousands of
years. With the aid of scientific research, Endocan Corporation is
translating such knowledge into development of effective
cannabinoid formulation-based health and wellness solutions as well
as cosmeceutical, nutraceutical, and food brands throughout the
world. The Company's health and wellness, nutritional, and
cosmetics lines will address personal needs and will evolve with
the introduction of new formulations and products, advancing the
Company within the expanding multibillion-dollar global market.
Forward Looking Statements
This Press Release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Act of 1934. A statement containing
words such as "anticipate," "seek," intend," "believe," "plan,"
"estimate," "expect," "project," "plan," or similar phrases may be
deemed "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Some or all of
the events or results anticipated by these forward-looking
statements may not occur. Factors that could cause or contribute to
such differences include the future U.S. and global economies, the
impact of competition, and the Company's reliance on existing
regulations regarding the use and development of cannabis-based
drugs. The Company does not undertake any duty nor does it intend
to update the results of these forward-looking statements.
Endocan Corporation
President
Dr. Dorothy Bray
info@endocan.com
www.endocan.com
+1.866.326.5595
Investment Inquiries
Robert Kane
CFO, Sr Vp of Business Development
robert.kane@endocan.com
+1.561.420.4824
SOURCE Endocan Corporation